| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1294 | 2013 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1135 | 2011 |
| Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA GR Oxnard, CP Paweletz, Y Kuang, SL Mach, A O'Connell, MM Messineo, ... Clinical cancer research 20 (6), 1698-1705, 2014 | 848 | 2014 |
| A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors T Sasaki, J Koivunen, A Ogino, M Yanagita, S Nikiforow, W Zheng, ... Cancer research 71 (18), 6051-6060, 2011 | 706 | 2011 |
| Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer A Vaishnavi, M Capelletti, AT Le, S Kako, M Butaney, D Ercan, S Mahale, ... Nature medicine 19 (11), 1469-1472, 2013 | 686 | 2013 |
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ... Nature 483 (7391), 613-617, 2012 | 497 | 2012 |
| Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer S Cardarella, A Ogino, M Nishino, M Butaney, J Shen, C Lydon, BY Yeap, ... Clinical cancer research 19 (16), 4532-4540, 2013 | 421 | 2013 |
| Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions GR Oxnard, PC Lo, M Nishino, SE Dahlberg, NI Lindeman, M Butaney, ... Journal of Thoracic Oncology 8 (2), 179-184, 2013 | 359 | 2013 |
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ... Cancer discovery 2 (10), 934-947, 2012 | 326 | 2012 |
| Dissemination of misinformative and biased information about prostate cancer on YouTube S Loeb, S Sengupta, M Butaney, JN Macaluso Jr, SW Czarniecki, ... European urology 75 (4), 564-567, 2019 | 260 | 2019 |
| Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer A Calles, X Liao, LM Sholl, SJ Rodig, GJ Freeman, M Butaney, C Lydon, ... Journal of thoracic oncology 10 (12), 1726-1735, 2015 | 254 | 2015 |
| Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis CJD Wallis, M Butaney, R Satkunasivam, SJ Freedland, SP Patel, ... JAMA oncology 5 (4), 529-536, 2019 | 219 | 2019 |
| ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas LM Sholl, H Sun, M Butaney, C Zhang, C Lee, PA Jänne, SJ Rodig The American journal of surgical pathology 37 (9), 1441-1449, 2013 | 214 | 2013 |
| The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non–small cell lung cancer with EGFR mutations S Heon, BY Yeap, NI Lindeman, VA Joshi, M Butaney, GJ Britt, DB Costa, ... Clinical Cancer Research 18 (16), 4406-4414, 2012 | 202 | 2012 |
| A functional landscape of resistance to ALK inhibition in lung cancer FH Wilson, CM Johannessen, F Piccioni, P Tamayo, JW Kim, ... Cancer cell 27 (3), 397-408, 2015 | 184 | 2015 |
| Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers HW Cheung, J Du, JS Boehm, F He, BA Weir, X Wang, M Butaney, ... Cancer discovery 1 (7), 608-625, 2011 | 148 | 2011 |
| The introduction of systematic genomic testing for patients with non–small-cell lung cancer S Cardarella, TM Ortiz, VA Joshi, M Butaney, DM Jackman, ... Journal of Thoracic Oncology 7 (12), 1767-1774, 2012 | 114 | 2012 |
| Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma A Calles, LM Sholl, SJ Rodig, AK Pelton, JL Hornick, M Butaney, C Lydon, ... Clinical Cancer Research 21 (12), 2851-2860, 2015 | 110 | 2015 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3: 1355–1363. doi: 10.1158/2159-8290 EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... CD-13-0310.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 88 | |
| Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. AT Shaw, BY Yeap, BJ Solomon, GJ Riely, AJ Iafrate, G Shapiro, ... Journal of Clinical Oncology 29 (15_suppl), 7507-7507, 2011 | 85 | 2011 |
